Welcome to our dedicated page for Biotage Ab news (Ticker: BITGF), a resource for investors and traders seeking the latest updates and insights on Biotage Ab stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biotage Ab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biotage Ab's position in the market.
On October 20, 2021, Biotage announced the acquisition of ATDBio for approximately 45 MGBP (534.4 MSEK). This acquisition aims to enhance Biotage's capabilities in DNA and RNA oligonucleotide synthesis and purification, crucial for drug discovery and molecular diagnostics. The deal is financed through a mix of newly issued shares and cash. ATDBio, founded by Tom Brown Sr. in 2004, generated 3.5 MGBP in sales in 2020 and shows potential for growth in the expanding nucleic acid sector, driven by increased demand amidst the pandemic.
Biotage has launched the Biotage® PhyPrep, an automated platform for plasmid DNA purification. This innovation aims to enhance laboratory efficiency by minimizing manual errors and improving yield consistency. The system empowers biopharma labs to handle plasmid purification in-house, which can lower costs and improve project deliverability. Operating at Maxi, Mega, and Giga scales, it processes plasmid yields from 1 mg to 10 mg. CEO Tomas Blomquist emphasized that this launch aligns with Biotage's mission to support the discovery of new therapies.
Biotage reports strong growth with net sales of 281.4 MSEK, up 1.4% YoY, while organic growth surged by 12%. The operating profit of 79.4 MSEK reflects a margin of 28.2%, a record high. Despite a slight dip in net profit to 60.0 MSEK, cash flow from operations increased, enhancing the net cash position to 189.6 MSEK. The Scale-up product area saw a remarkable 16.4% growth, driven by collaborations in vaccine development. However, the Analytical chemistry segment declined by 11.4% due to pandemic impacts.
FAQ
What is the current stock price of Biotage Ab (BITGF)?
What is the market cap of Biotage Ab (BITGF)?
